GMP Regulatory Newsletter: Summary Scan | Week of 3/4/18

[fusion_builder_container hundred_percent=”no” equal_height_columns=”no” menu_anchor=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” background_color=”” background_image=”” background_position=”center center” background_repeat=”no-repeat” fade=”no” background_parallax=”none” parallax_speed=”0.3″ video_mp4=”” video_webm=”” video_ogv=”” video_url=”” video_aspect_ratio=”16:9″ video_loop=”yes” video_mute=”yes” overlay_color=”” video_preview_image=”” border_size=”” border_color=”” border_style=”solid” padding_top=”” padding_bottom=”” padding_left=”” padding_right=””][fusion_builder_row][fusion_builder_column type=”1_1″ layout=”1_1″ background_position=”left top” background_color=”” border_size=”” border_color=”” border_style=”solid” border_position=”all” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding_top=”” padding_right=”” padding_bottom=”” padding_left=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” center_content=”no” last=”no” min_height=”” hover_type=”none” link=””][fusion_text]

Laws, Regulations, Guidance, and Concept Papers

It was a light week on the guidance front particularly from the EMA and the FDA. On the other hand:

  • WHO published two drafts.
  • Health Canada published a final revision to their drug GMPs.
  • And, perhaps more important than all (I admit I’m prejudiced on the topic), is the final version of the MHRA GXP Guidance on Data Integrity.

The non-guidance publication was also light this week, but there were contributions from FDA, EMA, MHRA, and CDSCO who published Q&As on their new medical device requirements.

To see the complete list of laws, regulations, guidance, and concept papers published this week, start your FREE GMP Regulatory Intelligence Trial today.


Enforcement information included:

  • Two warning letters to finished pharmaceutical manufacturers, both located outside the US.
  • One letter to a compounding pharmacy.
  • Three warning letters to manufacturers of duodenoscopes (remember them?) for failures in post approval safety reporting.

There were also three forms 483 issued to drug firms and one issued to a device firm. The latter is extensive and focuses on investigation of customer complaints. FDA published recalls in all classes. Hospira also had a yet unclassified recall for cracked or empty vials. Import alerts were put in place for failure to comply with drug GMPs, distributing unapproved drug products in the US, and delaying or impeding an FDA inspection.

Learn more about how FDAzilla can help you achieve your quality and inspection preparation goals: get 483sInspector ProfilesEnforcement Analytics, and GMP Regulatory Intelligence. Contact us if you ever have questions at

Subscribe to our monthly newsletter for regulatory and quality insights and developments.

[/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container][fusion_global id=”1646″][fusion_global id=”1657″]

Like this post? Don't forget to share it!

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Govzilla Bug

Don’t miss out! Subscribe now

Experience the Power of Govzilla

Get your FREE account to search sites, inspections, & warning letters